Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ SalesGlobeNewsWire • 05/08/25
Elutia Transitions to Direct Distribution of Its Cardiovascular Product PortfolioGlobeNewsWire • 05/01/25
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025GlobeNewsWire • 05/01/25
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29GlobeNewsWire • 04/22/25
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical PracticeGlobeNewsWire • 04/21/25
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology MakesGlobeNewsWire • 04/02/25
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™GlobeNewsWire • 03/27/25
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic EnvelopeGlobeNewsWire • 03/25/25
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-OutGlobeNewsWire • 03/06/25
Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025GlobeNewsWire • 02/20/25
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30GlobeNewsWire • 10/23/24
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable DevicesGlobeNewsWire • 09/18/24
Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and NeurostimulatorsGlobeNewsWire • 09/05/24
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register NowGlobeNewsWire • 08/20/24